FY2024 Earnings Forecast for Agenus Issued By William Blair

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at William Blair upped their FY2024 EPS estimates for shares of Agenus in a note issued to investors on Monday, January 27th. William Blair analyst M. Phipps now expects that the biotechnology company will post earnings of ($14.59) per share for the year, up from their previous estimate of ($15.34). The consensus estimate for Agenus’ current full-year earnings is ($12.93) per share. William Blair also issued estimates for Agenus’ Q4 2024 earnings at ($2.37) EPS, Q1 2025 earnings at ($1.31) EPS, Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.85) EPS, Q4 2025 earnings at ($0.76) EPS, FY2025 earnings at ($3.92) EPS, FY2026 earnings at ($2.91) EPS and FY2027 earnings at ($2.83) EPS.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Agenus has a consensus rating of “Hold” and an average price target of $10.00.

Agenus Stock Performance

NASDAQ AGEN opened at $3.61 on Thursday. Agenus has a twelve month low of $2.50 and a twelve month high of $19.69. The firm’s 50 day moving average price is $3.23 and its two-hundred day moving average price is $4.62. The stock has a market cap of $84.69 million, a price-to-earnings ratio of -0.32 and a beta of 1.27.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Apollon Wealth Management LLC acquired a new position in shares of Agenus during the fourth quarter valued at about $55,000. Barclays PLC increased its stake in Agenus by 295.3% in the third quarter. Barclays PLC now owns 27,813 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 20,777 shares during the period. Geode Capital Management LLC increased its stake in Agenus by 7.1% in the third quarter. Geode Capital Management LLC now owns 483,059 shares of the biotechnology company’s stock valued at $2,648,000 after acquiring an additional 32,016 shares during the period. EP Wealth Advisors LLC bought a new stake in Agenus in the third quarter valued at about $55,000. Finally, State Street Corp increased its stake in Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after acquiring an additional 9,731 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.